Related Experiment Videos
Thrombolysis and antithrombotic therapy for coronary artery disease
1Hebrew Hospital Home, Bronx and Valhalla, New York, USA.
Insights
Daily aspirin is recommended for acute myocardial infarction (MI) management and secondary prevention. Other therapies like thrombolytics, angioplasty, and anticoagulants are used based on patient specifics and risk factors.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (MI) and related coronary events pose significant health risks.
- Effective management strategies are crucial for improving patient outcomes and preventing recurrent events.
Purpose of the Study:
- To outline evidence-based recommendations for the pharmacological and interventional management of acute myocardial infarction (MI).
- To provide guidance on secondary prevention strategies for patients post-MI and those with other coronary artery diseases.
Main Methods:
- Review and synthesis of current clinical guidelines and research findings on MI treatment.
- Analysis of therapeutic interventions including antiplatelet agents, thrombolytics, anticoagulants, and revascularization procedures.
Main Results:
- Aspirin (160-325 mg daily) is foundational for acute MI and long-term secondary prevention.
- Thrombolytic therapy or primary percutaneous coronary intervention (PCI) is indicated within hours of ST-elevation MI.
- Heparin, warfarin, and glycoprotein IIb/IIIa inhibitors are used in specific high-risk scenarios or post-procedural care.
Conclusions:
- A multi-faceted approach combining antiplatelet therapy, timely revascularization, and anticoagulation where indicated, is essential for optimal MI management.
- Long-term aspirin use is recommended for secondary prevention in various cardiovascular conditions, including post-MI and angina.
Abstract:
Aspirin in a dose of 160 to 325 mg should be administered on day 1 of an acute MI and continued indefinitely on a daily basis. Thrombolytic therapy should be administered within 6 to 12 hours after the onset of an acute MI with ST segment elevation or with left bundle branch block. Primary coronary angioplasty when available should be used rather than thrombolytic therapy in the treatment of older persons with acute MI who are poor candidates for thrombolytic therapy. Intravenous heparin should be given in persons with acute MI undergoing primary coronary angioplasty or surgical coronary revascularization and in persons with acute MI at high risk for systemic embolization. Long-term oral warfarin should be given after MI for the secondary prevention of MI in post-MI persons unable to tolerate daily aspirin, in post-MI persons with persistent atrial fibrillation, and in post-MI persons with left ventricular thrombus. Platelet GP IIb/IIIa inhibitors should be administered along with aspirin and enoxaparin in the acute phase of management of persons with unstable angina pectoris or non-Q wave MI. Aspirin should be administered daily indefinitely to persons after MI, to persons with unstable angina pectoris, to persons with stable angina pectoris, and to persons undergoing coronary revascularization. Aspirin plus ticlopidine or aspirin plus clopidogrel should be used in persons undergoing coronary artery stenting. Platelet GP IIb/IIIa inhibitors should be used at the time of coronary angioplasty, coronary atherectomy, or coronary stenting. Aspirin, 160 to 325 mg daily, is recommended in older men and postmenopausal women who are at high risk for developing coronary events in addition to treating their coronary risk factors.